Bristol Myers Squibb stock is trading just below 67 dollars on the NYSE after a recent 1.9 percent d

VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 1,722,230 shares of the biopharmaceutical comp

Paralel Advisors LLC purchased a new position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 38,091 shares of the biopharmaceut

TD Waterhouse Canada Inc. boosted its stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 194.9% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 81,526 shares of the biopharm

Compass Financial Management LLC purchased a new position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 14,966 shar

Bristol Myers Squibb stock held close to USD 66.78 after a Q2 2026 beat, while the company kept FY 2

Bristol-Myers Squibb stock is trading near its recent highs as Q1 2026 revenue growth, a stronger po

Saudi Central Bank raised its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 90.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 142,922 shares of the biopharmaceutica

Mid American Wealth Advisory Group Inc. lowered its position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 27.8% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 58,193 shares of the biopharmaceutical company

Bristol-Myers Squibb (BMY) is in focus after two contrasting clinical updates. Fresh five year data on Camzyos in obstructive hypertrophic cardiomyopathy landed alongside a voluntary enrollment pause in zola-cel autoimmune trials. For context, Bristol-Myers Squibb’s share price has climbed 16.68% over the past 90 days and 24.99% year to date, while the 1 year total shareholder return of 48.55% points to momentum that has been building through recent clinical data, guidance updates, and the...

Bristol-Myers Co. y Squibb Corp. se fusionaron en 1989 para formar lo que hoy es una de las compañías farmacéuticas más grandes del mundo. Bristol-Myers Squibb desarrolla, otorga licencias, fabrica y distribuye productos biofarmacéuticos para el tratamiento y manejo de enfermedades como el VIH/SIDA, el cáncer, los trastornos sanguíneos y las afecciones cardiovasculares y fibróticas.

Munich Reinsurance Co Stock Corp in Munich lifted its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 9.8% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 347,582 shares of the biopharmaceutical company

NEOS Investment Management LLC increased its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 11.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 331,429 shares of the b

Concurrent Investment Advisors LLC boosted its holdings in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 29.6% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 266,252 shares of the biopharmaceuti

In the most recent trading session, Bristol Myers Squibb (BMY) closed at $66.82, indicating a -1.87% shift from the previous trading day.

In late August 2026, Bristol Myers Squibb reported five-year EXPLORER-LTE data at ESC Congress showing sustained efficacy and consistent safety for Camzyos in symptomatic obstructive hypertrophic cardiomyopathy, supported by multiple real-world studies across several countries. The combination of long-term trial outcomes and real-world evidence strengthens Camzyos’ position within the cardiac myosin inhibitor class and may influence how clinicians manage obstructive hypertrophic...

Bristol-Myers Squibb stock is holding in the upper-60 USD range after a pause in CAR-T autoimmune tr